Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research and Development »
« Back
Partnerships
Careers
Citizenship »
« Back
- Scientist Development Program
- Aclaris Support
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research and Development »
« Back
Partnerships
Careers
Citizenship »
« Back
- Scientist Development Program
- Aclaris Support
Investors »
« Back

Aclaris - Investor Relations

Investor Overview
Stock Information
Press Releases
Events
SEC Filings
Corporate Governance
Investor Presentations
Investor FAQs
Email Alerts

Investor Contact

For investor related questions, please email

investors@aclaristx.com

Investor Overview

Stock quote

VOLUME:

View stock performance »

Minimum 15 minutes delayed. Source: LSEG

Investor Overview

Press Releases

September 3, 2026

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

August 6, 2026

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

August 6, 2026

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Events

Sep 10, 2026
2:45 PM EDT

2026 Cantor Global Healthcare Conference

Jun 4, 2026
2:00 PM EDT

Jefferies Global Healthcare Conference

May 14, 2026
9:35 AM PDT

Bank of America 2026 Global Healthcare Conference

Feature Presentation

Corporate Update Presentation

August 2026 Corporate Presentation

Aclaris - Footer Menu

Terms of Use
Privacy Policy
Contact Us
Fraudulent Activity Notice

© 2026 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.